Drug Profile
Research programme: nalmefene sustained release - Johnson and Johnson
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Johnson & Johnson
- Class Anti-inflammatories; Opioid analgesics
- Mechanism of Action Opioid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alcoholism
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alcoholism in Belgium (IM)
- 13 Nov 2010 Preclinical trials in Alcoholism in Belgium (IM)